- May 31, 2019
Event LocationWhite Oak Campus: The Great Room
10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
- Organized By:
The Food and Drug Administration held a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. See the Federal Register notice for more information.
Dr. Sharpless’ opening remarks are now available.
A webcast recording is available in four distinct segments. Each segment is in order based on the agenda.
- Opening until morning break
- After morning break until lunch
- After lunch until afternoon break
- After afternoon break until closing
The transcript is available for the Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds Public Hearing.
FDA established a docket for public comment on this hearing.The docket number is FDA-2019-N-1482. On June 20, 2019, the comment period was extended and the docket will now close on July 16, 2019. See the Federal Register announcement for more information. Submit either electronic or written comments on this public hearing by July 16, 2019. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before July 16, 2019.The Regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 16, 2019. Comments received by mail/ hand delivery/ courier (for written/ paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.